Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5325-5330

  Xiong, Yan Q ^a,b   Hady, Wessam Abdel ^a   Deslandes, Antoine ^c   Rey, Astrid ^c   Fraisse, Laurent ^c   Kristensen, Hans Henrik ^d   Yeaman, Michael R ^a,b   Bayer, Arnold S ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANOFI   (France)

^d NOVOZYMES A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; NZ 2114; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXPERIMENTAL RABBIT; KIDNEY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPLEEN; STEADY STATE;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ENDOCARDITIS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; RABBITS; RANDOM ALLOCATION; STAPHYLOCOCCAL INFECTIONS;

EID: 80054683955     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00453-11     Document Type: Article

References (28)

1. Andes, D., W. Craig, L. A. Nielsen, and H. H. Kristensen. 2009. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob. Agents Chemother. 53:3003-3009.
2. Bayer, A. S., and K. Lam. 1985. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J. Infect. Dis. 151:157-165. (Pubitemid 15192894)
3. Bengualid, V., V. B. Hatcher, B. Diamond, E. A. Blumberg, and F. D. Lowy. 1990. Staphylococcus aureus infection of human endothelial cells potentiates Fc receptor expression. J. Immunol. 145:4279-4283.
4. Brinch, K. S., N. Frimodt-Møller, N. Høiby, and H. H. Kristensen. 2009. Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics. Antimicrob. Agents Chemother. 53:4794-4800.
5. Brinch, K. S., et al. 2009. Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model. Antimicrob. Agents Chemother. 53:4801-4808.
6. Brinch, K. S., et al. 2010. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. J. Antimicrob. Chemother. 65:1720-1724.
7. Chambers, H. F., et al. 2009. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob. Agents Chemother. 53:1463-1467.
8. Chang, S., et al. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347. (Pubitemid 36384101)
9. Chavakis, T., K. Wiechmann, K. T. Preissner, and M. Herrmann. 2005. Staphylococcus aureus interactions with the endothelium: the role of bacterial "secretable expanded repertoire adhesive molecules" (SERAM) in disturbing host defense systems. Thromb. Haemost. 94:278-285. (Pubitemid 41122481)
10. Cirić, B., et al. 2010. Simultaneous determination of amoxicillin and clavulanic acid in the human plasma by high performance liquid chromatographymass spectrometry (UPLC/MS). Vojnosanit. Pregl. 67:887-892. (In Serbian.)
11. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. Clinical and Laboratory Standards Insitute, Wayne, PA.
12. Dhawan, V. K., M. R. Yeaman, and A. S. Bayer. 1999. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis. J. Infect. Dis. 180:1561-1568. (Pubitemid 29506458)
13. El-Ahdab, F., et al. 2005. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am. J. Med. 118:225-229. (Pubitemid 40312632)
14. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. (Pubitemid 44967479)
15. Hardy, K. J., P. M. Hawkey, F. Gao, and B. A. Oppenheim. 2004. Methicillin resistant Staphylococcus aureus in the critically ill. Br. J. Anaesth. 92:121-130. (Pubitemid 38054659)
16. Haste, N. M., et al. 2011. Bactericidal kinetics of marine-derived napyradiomycins against contemporary methicillin-resistant Staphylococcus aureus. Mar. Drugs 9:680-689.
17. Liñares, J. 2001. The VISA/GISA problem: therapeutic implications. Clin. Microbiol. Infect. 7(Suppl. 4):8-15. (Pubitemid 34966103)
18. Menichetti, F. 2005. Current and emerging serious Gram-positive infections. Clin. Microbiol. Infect. 11(Suppl. 3):22-28. (Pubitemid 40946175)
19. Mygind, P. H., et al. 2005. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437:975-980. (Pubitemid 41486973)
20. Ostergaard, C., D. Sandvang, N. Frimodt-Moller, and H. H. Kristensen. 2009. High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of NZ2114, a novel plectasin variant, during experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 53:1581-1585.
21. Schneider, T., et al. 2010. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328:1168-1172.
22. Schwaber, M. J., et al. 2003. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg. Infect. Dis. 9:657-664. (Pubitemid 36676360)
23. Sinha, B., and M. Herrmann. 2005. Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb. Haemost. 94:266-277. (Pubitemid 41122480)
24. Xiong, Y. Q., et al. 2009. Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J. Infect. Dis. 199:201-208.
25. Xiong, Y. Q., et al. 2005. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob. Agents Chemother. 49:380-387. (Pubitemid 40065815)
26. Xiong, Y. Q., et al. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-2076.
27. Young, L. S., F. Perdreau-Remington, and L. G. Winston. 2004. Clinical, epidemiologic, and molecular evaluation of a clonal outbreak of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 38:1075-1083. (Pubitemid 38951251)
28. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. (Pubitemid 34100944)